Bridge City Capital LLC Boosts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Bridge City Capital LLC grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 94,997 shares of the specialty pharmaceutical company’s stock after purchasing an additional 761 shares during the period. Bridge City Capital LLC owned approximately 0.17% of Supernus Pharmaceuticals worth $3,435,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares during the period. Newbridge Financial Services Group Inc. purchased a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $72,000. Venturi Wealth Management LLC bought a new position in Supernus Pharmaceuticals in the 4th quarter worth about $92,000. KBC Group NV grew its holdings in Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after buying an additional 929 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at $211,000.

Supernus Pharmaceuticals Trading Down 0.5 %

SUPN opened at $32.15 on Friday. The stock has a market capitalization of $1.79 billion, a P/E ratio of 30.05 and a beta of 0.83. The stock has a 50-day moving average price of $35.68 and a 200-day moving average price of $35.07. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28.

Insider Buying and Selling

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 in the last quarter. 9.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SUPN shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, March 16th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.